XXXX and @entity1215 combination therapy for hidradenitis suppurativa.

@entity1 @entity1214 @entity1751 @entity1215 @entity3402
BACKGROUND: @entity1751 ( @entity1751 ) is a chronic inflammatory condition affecting apocrine gland-bearing areas of the skin. There is currently no satisfactory treatment. OBJECTIVES: To assess the efficacy of a 10-week course of combination @entity3402 300 mg twice daily and @entity1215 300 mg twice daily in the treatment of @entity1751 . METHODS: @entity1 who had received combination therapy with @entity3402 and @entity1215 for @entity1751 at one U.K. Dermatology Centre between the years 1998 and 2003 were identified from pharmacy records. Their records were analysed retrospectively. RESULTS: Fourteen @entity1 with @entity1751 had received treatment with combination therapy. Eight of these @entity1 achieved remission and a further two achieved remission when @entity1214 was substituted for @entity3402 . Four @entity1 were unable to tolerate therapy. CONCLUSIONS: This small retrospective study indicates that combination therapy with @entity3402 and @entity1215 may be effective for @entity1751 . However, there is a need for a placebo-controlled trial.
